瑞舒伐他汀对急性冠脉综合征患者血清几丁质酶-3样蛋白-1浓度的影响

目的探讨急性冠脉综合征（acute coronary syndrome，ACS）患者使用瑞舒伐他汀治疗2周后对血清几丁质酶-3样蛋白-1（chitinase 3-like protein1，YKL-40）浓度的影响。方法选取2011年1月至2012年12月莱州市人民医院收治的ACS患者120例，分为3组，每组40例，均予硝酸酯、拜阿司匹林、β受体阻断药、低分子肝素等常规治疗。A组给予常规治疗，B组在常规治疗基础上予瑞舒伐他汀10mg／d，C组在常规治疗基础上给予瑞舒伐他汀20mg／d。所有患者在治疗前、治疗2周后分别测定血脂、血糖和血清YKL-40浓度。结果A组治疗前、后血清总胆固醇、三酰甘油、低密度脂蛋白胆固醇浓度比较，差异无统计学意义（P〉0．05），而治疗后的血清YKL-40浓度比治疗前明显降低，差异有统计学意义（P〈0．05）。B组、C组治疗2周后血清总胆固醇、三酰甘油、低密度脂蛋白胆固醇浓度比治疗前明显降低，差异有统计学意义（P〈0．05），但血清YKL-40浓度的降低幅度更大（P〈0．01）。结论瑞舒伐他汀能明显降低血清YKL-40浓度，其效应随剂量的增加而增强。

Effect of rosuvastatin on serum concentration of chitinase 3-like protein 1 in patients with acute coronary syndrome

Objectives To investigate the effect of taking different doses of rosuvastatin for two weeks on serum concentration of chitinase 3-like protein 1 （YKL-40） in patients with acute coronary syndrome （ACS）. Methods Totally 120 patients with ACS in our hospital from January 2011 to December 2012 were divided into three groups randomly, 40 patients each. All of them were given nitroglycerin, isosorbide dinitrate, enteric-coated aspirin and low-molecular heparin as general therapy. Group A was given general therapy, Group B was added rosuvastatin （10 mg/d） to general therapy, and Group C was added rosuvastatin （20 mg/d） to general therapy. Serum soneentration of YKL-40, blood glucose and fat of the patients were detected before and after two weeks＇ treatment. Results There was no significant difference among the levels of total cholesterol （TC）, triglyceride （TG）, low density lipoprotein cholestord （LDL-C） in group A before and after treatment （P〉 0.05 ）, and serum concertration of YKL-40 decreased significantly after general therapy （P〈0.05）. The serum concentration of TC, TG, LDL-C and YKL-40 decreased significantly after two weeks＇ therapy compared in group B and C （P〈0.05）, meanwhile, with the increasing dose of rosuvastatin, serum concentration of YKL-40 decreased more significantly （P〈0.01）. Conclusions Rosuvastatin can significantly decrease the level of YKL-40 in patients with ACS, and the treatment effectiveness can be enhanced by increasing the dose of rosuvastatin.